Disease/Infection News

RSS

Gas naturally produced within our bodies reduces severity of RSV infection, UTMB study finds

A new study from the University of Texas Medical Branch at Galveston is the first to show that hydrogen sulfide, a gas produced naturally within our bodies, reduces the severity of respiratory syncytial virus, or RSV.

28 Apr 2015

OpenMRS community drives the world's largest open source project to tackle Ebola virus

An accurate, up to the minute, accessible medical record system is fundamental to effective treatment and tracking of the Ebola virus.

28 Apr 2015

Consortium of researchers awarded NIH grant to establish District of Columbia Center for AIDS Research

An interdisciplinary, city-wide consortium of researchers, led by Alan E. Greenberg, MD, MPH, professor and chair, Department of Epidemiology and Biostatistics at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University, has received a grant from the National Institutes of Health for an expected $7.5 million over five years to fund the newly established District of Columbia Center for AIDS Research.

28 Apr 2015

Two thirds of the world’s population have no access to safe and affordable surgery

New estimates suggest that number of people worldwide who are unable to access basic surgery and anaesthesia is more than twice as high as previously thought.

27 Apr 2015

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.

27 Apr 2015

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance.

27 Apr 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark.

27 Apr 2015

Many transgender people refrain from going to health care providers to avoid social stigma

Discussing your sexual history with a doctor, or anyone for that matter, can be an uncomfortable experience. But for many transgender people, the conversation never takes place because they aren't seeking health care, according to Adrian Juarez, PhD, a public health nurse and assistant professor in the University at Buffalo School of Nursing.

27 Apr 2015

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence.

27 Apr 2015

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

A new study revealed today at The International Liver Congress 2015 shows that sofosbuvir (SOF)-based regimens are effective and well tolerated in hepatitis C and HIV co-infected, cirrhotic patients. Sustained virologic response at 4 weeks (SVR4) was observed in 98% of patients and in 95% at 12 weeks (SVR12).

27 Apr 2015

Combination treatment effective for HCV genotype-1 mono-infected patients

Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These results are significant because whilst other combinations have been widely reported on, there have been few data until now regarding the use of SOF/DCV combination in real world situations.

25 Apr 2015

New data supports use DAAs in patients with HCV recurrence following liver transplantation

New data presented today at The International Liver Congress 2015, supports the use of sofosbuvir (SOF)- and daclatasvir (DCV)-based regimens in patients with recurrence of the hepatitis C virus (HCV) following liver transplantation (LT).

25 Apr 2015

Systematic review shows hepatitis B and C testing lacking in many European countries

The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver Congress 2015.

25 Apr 2015

Occurrence of advanced liver fibrosis similar for patients with HCV infection

Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.

25 Apr 2015

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Results presented today at The International Liver Congress 2015, show that alcohol use disorders (AUD) have a serious, negative prognostic outcome with higher mortality risks in the general population and patients with hepatitis C virus (HCV) infection in particular.

25 Apr 2015

Multicentre study provides hope for malaria therapy with just one dose

Approximately 584,000 people worldwide die of malaria each year. The epidemic strongly associated with poverty claims most of its victims in Africa, where it particularly affects the weakest, children and pregnant women. Current therapies have to be taken over several days to be effective against malaria.

25 Apr 2015

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

AbbVie has announced that the U.S. Food and Drug Administration has accepted its New Drug Application (NDA) and granted priority review for the company's, all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV).

25 Apr 2015

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study.

25 Apr 2015

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).

25 Apr 2015

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Results announced today at The International Liver Congress 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.

25 Apr 2015

Disease/Infection News

Gas naturally produced within our bodies reduces severity of RSV infection, UTMB study finds

OpenMRS community drives the world's largest open source project to tackle Ebola virus

Consortium of researchers awarded NIH grant to establish District of Columbia Center for AIDS Research

Two thirds of the world’s population have no access to safe and affordable surgery

NanoViricides' anti-viral drug candidates show promise in lethal animal model of dermal herpes infection

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Many transgender people refrain from going to health care providers to avoid social stigma

Combination therapy effective in HCV patients with advanced cirrhosis and post-transplant recurrence

Sofosbuvir-based regimens effective in HIV-HCV co-infected, cirrhotic patients

Combination treatment effective for HCV genotype-1 mono-infected patients

New data supports use DAAs in patients with HCV recurrence following liver transplantation

Systematic review shows hepatitis B and C testing lacking in many European countries

Occurrence of advanced liver fibrosis similar for patients with HCV infection

AUDs have negative prognostic outcome with higher mortality risks in patients with HCV infection

Multicentre study provides hope for malaria therapy with just one dose

AbbVie's all-oral, interferon-free therapy granted FDA priority review for treatment of GT4 HCV infection

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Study shows NASH linked to 50% higher death rates compared with NAFLD

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News